Patents Examined by K. Weddington
  • Patent number: 5854208
    Abstract: The invention provides an analogue of a pharmaceutical active whose molecular weight is less than 25,000 Daltons, the analogue comprising a pharmaceutical active whose molecular weight is less than 25,000 Daltons covalently linked to a pendant molecular group wherein as a result of the administration of the composition to the human or animal body an active complex having a molecular weight of 25,000 Daltons or greater is present in the human or animal circulatory system. The analogue is hepatoselective when administered to the circulatory system. Preferably the analogue is an insulin analogue comprising an insulin or functional equivalent thereof covalently linked to the pendant molecular group wherein the active complex is an insulin complex. Such an insulin analogue may be used in a method of insulin replacement therapy.
    Type: Grant
    Filed: February 13, 1996
    Date of Patent: December 29, 1998
    Assignees: Deutsches Wollforschungsinstitut, Kings College
    Inventors: Richard Henry Jones, Fariba Shojaee-Moradi, Peter Henri Sonksen, Dietrich Brandenburg, Achim Schuttler, Heike Eckey
  • Patent number: 5616580
    Abstract: This invention discloses mixtures of NMDA antagonists and anti-cholinergic agents, which can be used to prevent excitotoxic damage in the central nervous system or for anesthetic purposes in human or veterinary medicine. Anti-cholinergic agents such as scopolamine, atropine, benztropine, trihexyphenidyl, biperiden, procyclidine, benactyzine, or diphenhydramine can be used in conjunction with, or subsequent to, administration of an NMDA antagonist such as MK-801. The NMDA antagonist exerts a primary protective effect by preventing or reducing excitotoxic damage due to stroke, perinatal asphyxia, and various other types of injury or disease; however, strong NMDA antagonists such as MK-801 can also cause neurotoxic side effects, including vacuole formation, mitochondrial dissolution, and neuronal death in certain types of neurons such as cingulate/retrosplenial cerebrocortical neurons.
    Type: Grant
    Filed: April 26, 1991
    Date of Patent: April 1, 1997
    Inventor: John W. Olney
  • Patent number: 5516761
    Abstract: There is disclosed a topical multiple-point-application formulation containing a solution of a polymeric material and an avermectin compound (active ingredient) which has been discovered to provide superior efficacy against ectoparasites, such as fleas and ticks and endoparasites such as nematodes and heartworms, when compared to conventional formulations. The formulation contains the avermectin active ingredient and up to 50% of the polymeric material.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: May 14, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Hoo-Kyun Choi, James B. Williams
  • Patent number: 5504084
    Abstract: Pharmaceutical for the treatment of skin disordersA compound of the formula I or II ##STR1## and physiologically tolerable salts of compound of the formula II are suitable for treatment of psoriasis.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: April 2, 1996
    Assignees: Hoechst Aktiengesellschaft, Hoechst-Roussel Pharmaceuticals, Inc.
    Inventors: Robert R. Bartlett, Klaus U. Weithmann, Ellen S. Kurtz
  • Patent number: 5500807
    Abstract: The present invention provides a predictive method for selecting organic compounds having useful pharmaceutical activity in a mammal. The method uses volume areas of similar molecules. When specific substituents of the test compound file predetermined volumes, the compound is subject to a binding assay. Only when the binding assay is positive, is the experimental compound recommended for further pharmaceutical evaluation. Example compounds are derivatives of 4-substituted 2,6-diiodophenols of the structure: ##STR1## where R.sup.1 and R.sup.2 are defined as aliphatic or substituted aliphatic moieties or aromatic or substituted aromatic moieties. Useful structures are described. The compounds have useful pharmaceutical properties to treat conditions in a human being, including hyperthyroidism, angina pectoris, arrythmia, and the like.
    Type: Grant
    Filed: February 21, 1992
    Date of Patent: March 19, 1996
    Assignee: The Regents of the University of California
    Inventors: Thomas N. Lavin, Mark F. Norman, Teri E. Klein, George Seibel
  • Patent number: 5494660
    Abstract: A new class of biologically-active copolymers is provided capable of affecting biological systems in many different ways. The biologically-active copolymers of the present invention also have a wide variety of effects on individual cells. The biologically-active copolymers are also effective against certain microorganisms. The biologically active copolymers of the present invention can be administered to animals to provide specific effects on certain microorganisms that reside in the gut of the animal. A preferred use is administering the biologically active copolymers of the present invention to poultry to reduce the number of Salmonella in the poultry gut. Another preferred use is treatment of surfaces to interfere with the adhesion of microorganisms to the surfaces.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: February 27, 1996
    Assignees: Emory University, Cytrx Corporation
    Inventors: Robert L. Hunter, R. Martin Emanuele, Robert H. Carpenter
  • Patent number: 5489579
    Abstract: The present invention is directed to a method for poteniating the therapeutic effects of selected NMDA antagonists.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: February 6, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Bruce M. Baron
  • Patent number: 5488059
    Abstract: A method to induce or enhance an erection or treat erectile dysfunction through the administration of a pyridylguanidine compound, preferably, N-cyano-N'(1,1-dimethyl propyl)-N"-3-pyridinyl guanidine, in low doses to the penis. Administration can be by injection into the corpus cavernosum of the penis or transdermal application.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: January 30, 1996
    Assignee: The Upjohn Company
    Inventor: Allen E. Buhl
  • Patent number: 5482973
    Abstract: A suppository comprising pranoprofen is disclosed. The suppository has analgesic or anti-inflammatory effects. Since pranoprofen is administered away from gastrointestinal tracts, application of the suppository is not accompanied by side effects such as peptic ulcer, bleeding in constipation, and diarrhea. It is particularly suitable for patients with disorders in digestive organs and infant patients. Pranoprofen is released constantly over a extended period of time.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: January 9, 1996
    Assignee: Dojin Iyaku-Kako Co., Ltd.
    Inventors: Yoichi Sawayanagi, Yutaka Kawamura
  • Patent number: 5480891
    Abstract: A method for treating diabetes mellitus comprising administering to a patient in need thereof a pharmaceutically acceptable inert carrier in combination with an effective amount for treating diabetes mellitus of a carbostyril compound or a pharmaceutically acceptable salt thereof of the formula: ##STR1## wherein R is a halogen atom, the position of substitution of the side chain in the carbostyril skeleton being at the 3- or 4-position and the bond between the 3-position and the 4-positions in the carbostyril skeleton being a single bond or a double bond.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: January 2, 1996
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Katsuya Yamasaki, Kazushi Sakurai, Kazue Akiyama
  • Patent number: 5478814
    Abstract: Hemorrhoidal compositions containing disaccharide polysulfate-aluminum compounds such as sucralfate, above or in combination with other hemorrhoidal products, as an agent effective for alleviating the symptoms of anorectal disease when topically applied to the human skin. Method for alleviating the symptoms of hemorrhoids in humans. Compositions containing disaccharide polysulfate-aluminum compounds such as sucralfate, alone or in combination with antibiotics, antifungal agents, anti-acne agents, or local anesthetics as an active agent effective in promoting the healing of wounds which are not anorectal when topically applied to the surface of a wound. Method for promoting healing at the surface of a wound in humans.
    Type: Grant
    Filed: March 22, 1993
    Date of Patent: December 26, 1995
    Assignee: Norman H. Oksman
    Inventor: Elias W. Packman
  • Patent number: 5474990
    Abstract: Certain barbiturates have been shown to completely prevent the neurotoxic injury to cerebrocortical neurons that can be caused by NMDA antagonists. The use of barbiturates as "safening agents" allows NMDA antagonists (including powerful NMDA antagonists such as MK-801) to be used safely as neuroprotectants to prevent brain damage due to hypoxia/ischemia caused by strokes, cardiac arrest, perinatal asphyxia, and various other conditions.
    Type: Grant
    Filed: July 22, 1991
    Date of Patent: December 12, 1995
    Inventor: John W. Olney
  • Patent number: 5471786
    Abstract: A mineral fibre containing plant growing medium comprising lignite has ion exchange capacity and improved water retention properties and does not require disinfection before use.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: December 5, 1995
    Assignee: Rockwool International A/S
    Inventor: Ulf A. Clausen
  • Patent number: 5468755
    Abstract: A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: November 21, 1995
    Assignee: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Anthony H. Cincotta, Albert H. Meier
  • Patent number: 5466718
    Abstract: Methods and compositions are provided for inhibiting the activity of tyrosinase in a host and, as a result, inhibiting melanin-formation. The tyrosinase-inhibitor active ingredient is a compound or mixture of compounds represented by the following structural formulae (I) and (II): ##STR1## wherein the dotted lines at a, b, c, d, e, f, g, represent an optional double bond, provided that double bonds are not at both b and c, or at both f and g, at the same time; R.sup.1, R.sup.5, R.sup.6, and R.sup.7 are each hydrogen or methyl; R.sup.2 and R.sup.8 are each no group, or each hydrogen or hydroxyl when there is no double bond at a and at f, respectively; R.sup.3 is methylene when there is a double bond at b, or hydrogen or methyl when there is no double bond at b; R.sup.4 is formyl or --(CH.sub.2).sub.n --R.sup.10, wherein R.sup.10 is hydrogen, hydroxyl, acyloxy, or cyano and n is an integer of from 1 to 3; and R.sup.9 is methylene when there is a double bond at g, or --(CH.sub.2).sub.n --R.sup.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: November 14, 1995
    Assignee: Takasago Institute for Interdisciplinary
    Inventors: Tetsuo Nakatsu, Kok Lean R. Kang, Kelly L. McAlister, Jiansheng Huang
  • Patent number: 5466445
    Abstract: A new class of biologically-active copolymers is provided capable of effecting biological systems in many different ways. The biologically active copolymers of the present invention also have a wide variety of effects on individual cells. The biologically active copolymers are also effective against certain microorganisms. The biologically active copolymers of the present invention can be administered to animals to provide specific effects on certain microorganisms that reside in the gut of the animal. A preferred use is administering the biologically active copolymers of the present invention to poultry to reduce the number of Salmonella in the poultry gut.
    Type: Grant
    Filed: July 21, 1993
    Date of Patent: November 14, 1995
    Assignee: Emory University
    Inventor: Robert L. Hunter
  • Patent number: 5464623
    Abstract: Insecticidal pellet compositions of N-hydrocarboyl phosphoroamidothioates and phosphoroamidodithioates are provided. These compositions have improved odor control, thermal stability, attrition resistance, bulk density and handling characteristics over the powdered forms of the insecticides. Methods are provided for making such pellets, and in particular, an extrusion method is provided in which the dry insecticidal composition is mixed with from 3-25% of a solvent to form a consistency of damp sandy loam and then extruded.
    Type: Grant
    Filed: August 18, 1989
    Date of Patent: November 7, 1995
    Assignee: Chevron Research Company
    Inventors: Jimmy H. Chan, Rodrick I. Satre, James H. Trusler, Sadanand G. Memula
  • Patent number: 5464636
    Abstract: Improved biocidal composition and method for controlling biofouling and microorganism population levels in recirculating water systems such as cooling towers, swimming pools or spas is disclosed and claimed. The composition comprises a hypochlorite donor and a bromide ion donor in proportions selected to maintain a mole ratio of the sum of all bromine containing species to the sum of all hypohalite species in the recirculating water of about 0.2 to about 20. The method comprises introducing into the recirculating water a mixture or combination of a hypochlorite donor and a bromide ion donor in an amount sufficient to maintain a ratio of the sum of all bromine containing species to the sum of all species in the recirculating water in the range of about 0.2 to about 20.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: November 7, 1995
    Assignee: The University of Houston
    Inventors: Terry V. T. Hight, Jack V. Matson, Lawrence F. Rakestraw, Zhihe Zhang, Thomas C. Kuechler
  • Patent number: RE35095
    Abstract: Seizures are ameliorated with certain benzothiazepines.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: November 21, 1995
    Assignee: Marion Laboratories, Inc.
    Inventors: Ray H. Zobrist, William R. Morrone
  • Patent number: RE35233
    Abstract: The invention relates to a method of treating a catabolic dysfunction in an animal, which comprises administering to an animal a therapeutically effective amount of glutamine, or an analog thereof.
    Type: Grant
    Filed: January 10, 1994
    Date of Patent: May 7, 1996
    Assignee: Brigham and Women's Hospital
    Inventors: Robert J. Smith, Douglas W. Wilmore